Potential Duchenne Muscular Dystrophy therapy from Exonics gets $5m boost
US based Exonics Therapeutics has secured $5 million seed funding from CureDuchenne Ventures, a subsidiary of nonprofit DMD advocacy group,
Continue readingCoverage of Global Pharma Industry News
US based Exonics Therapeutics has secured $5 million seed funding from CureDuchenne Ventures, a subsidiary of nonprofit DMD advocacy group,
Continue readingThe blood cancer drug for elderly patients, sapacitabine (CYC682) developed by New Jersey based Cyclacel Pharmaceuticals has failed to meet
Continue readingSymic Bio, a California based biopharma focued on matrix biology, is all set to begin the phase 1/2a clinical study
Continue readingSwiss pharma Novartis has announced that its lung cancer drug Zykadia (ceritinib) has been granted the FDA priority review for
Continue readingPfizer’s blood cancer drug, inotuzumab ozogamicin has secured a priority review designation from the US Food and Drug Administration (FDA).
Continue readingGSK Consumer Healthcare has rolled out a new over-the-counter OTC allergy relief spray in the US under the brand name,
Continue reading